August 18, 2009 — The US Food and Drug Administration (FDA) has approved a new indication for antihemophilic factor (recombinant) intravenous injection (Helixate FS, CSL Behring) for routine ...

250 Pages of Research Study Published by Fact.MR, a Leading Market Research and Competitive Intelligence Provider Offers Riveting Insights into Key Factors Accelerating the Growth of the Global ...

Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A- Bayer's SPINART study met its ...

Cryoprecipitate also known as cryoprecipitated antihemophilic factor is an insoluble material that emerges from a solution after frozen plasma is defrosted between 1°C and 6°C. Rich in specific plasma ...

FORT LEE, N.J.--(BUSINESS WIRE)--Kedrion Biopharma proudly announces that Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human) is now being manufactured using a process that further ...

EAGAN, Minn., Dec. 16, 2020 /PRNewswire/ -- In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC ...

New FDA-approved indications for ADYNOVATE provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule Shire plc (LSE: SHP, NASDAQ: SHPG) announced ...

First and only FDA-approved pharmacokinetic dosing software and patient app available for ADYNOVATE patients 12 and older and weighing at least 29 kg allows healthcare professionals to help provide ...

Report Ocean recently released a new report on the global Antihemophilic Factor Market. This study report is a combination of data and analysis gleaned from several sources to help businesses ...

It is the purpose of this paper to report on a young, phenotypically normal female with hemophilia A whose pattern of inheritance is unusual in that she is the offspring of a carrier female and a ...

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine ...